Screening of Specific Genes for Pigmented Villous Nodular Synovitis

This study retrospectively analyzed the history of present illness of PVNS patients in our hospital. The enrolled patients were followed up by telephone to follow up their postoperative recovery and living conditions. Take the patient's pathological specimens for immunohistochemical testing, evaluate the relationship between the expression of different molecular targets, clinical manifestations and patient prognosis, and explore new molecular targets related to disease diagnosis and treatment.

Study Overview

• Status: Completed
• Conditions: Pigmented Villonodular Synovitis
• Intervention / Treatment: Procedure: Arthroscopic synovectomy

Detailed Description

This study retrospectively analyzed the symptoms, time of onset, injury history, laboratory examinations, imaging examinations, and intraoperative conditions of PVNS patients in our hospital. The enrolled patients were followed up by telephone to follow up their postoperative recovery and living conditions (VAS score, SF-36 score). Take the patient's pathological specimens for immunohistochemical testing, evaluate the relationship between the expression of different molecular targets, clinical manifestations and patient prognosis, and explore new molecular targets related to disease diagnosis and treatment.

• Study Type: Observational
• Enrollment (Actual): 60

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100191
      • Institute of Sports Medicine, Peking University Third Hospital, Beijing Key Laboratory of Sports Injuries， Beijing, China

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients with "pigmented villonodular synovitis" and "giant cell tumor of tendon sheath"

Description

Inclusion Criteria:

1. Clinical diagnosis of pigmented villonodular synovitis.
2. Clinical diagnosis of giant cell tumor of tendon sheath

Exclusion Criteria:

1. No surgical treatment.
2. There were no pathological specimens during the operation.
3. The age of the patient is less than 18 years old or more than 60 years old.
4. The operation record shows nodular type.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference of scale score between immunohistochemistry positive group and negative group	Difference of Visual Analog Score for pain between CSF-1 immunohistochemistry positive group and negative group	One week after surgery
Difference of Visual Analog Score for pain between TNF-α immunohistochemistry positive group and negative group	Difference of Visual Analog Score for pain between TNF-α immunohistochemistry positive group and negative group	One week after surgery
Difference of Visual Analog Score for pain between IL-1B immunohistochemistry positive group and negative group	Difference of Visual Analog Score for pain between IL-1B immunohistochemistry positive group and negative group	One week after surgery
Difference of SF-36 score between CSF-1 immunohistochemistry positive group and negative group	Difference of SF-36 score between CSF-1 immunohistochemistry positive group and negative group	One week after surgery
Difference of SF-36 score between TNF-α immunohistochemistry positive group and negative group	Difference of SF-36 score between TNF-α immunohistochemistry positive group and negative group	One week after surgery
Difference of SF-36 score between IL-1B immunohistochemistry positive group and negative group	Difference of SF-36 score between IL-1B immunohistochemistry positive group and negative group	One week after surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation between basic demographic characteristics and scale scores	Correlation between age, gender and scale score	One week after surgery

Collaborators and Investigators

• Sponsor: Peking University Third Hospital
• Investigators: Study Chair: Yingfang Ao, Prof., Peking Yniversity Third Hospital

Study record dates

Study Major Dates

• Study Start (Actual): August 3, 2020
• Primary Completion (Actual): December 27, 2020
• Study Completion (Actual): December 27, 2020

Study Registration Dates

• First Submitted: June 25, 2021
• First Submitted That Met QC Criteria: July 7, 2021
• First Posted (Actual): July 8, 2021

Study Record Updates

• Last Update Posted (Actual): July 8, 2021
• Last Update Submitted That Met QC Criteria: July 7, 2021
• Last Verified: June 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Joint Diseases; Musculoskeletal Diseases; Muscular Diseases; Neoplasms, Connective Tissue; Tendinopathy; Giant Cell Tumor of Tendon Sheath; Giant Cell Tumors; Synovitis; Synovitis, Pigmented Villonodular
• Other Study ID Numbers: M201947901

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No